Vaxxinity (VAXX) Competitors $0.02 +0.02 (+19,900.00%) As of 03:38 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock VAXX vs. SYRS, NEXI, VRPX, SCPS, ARDS, NAVB, EVLO, CMRA, GNCAQ, and GNCAShould you be buying Vaxxinity stock or one of its competitors? The main competitors of Vaxxinity include Syros Pharmaceuticals (SYRS), NexImmune (NEXI), Virpax Pharmaceuticals (VRPX), Scopus BioPharma (SCPS), Aridis Pharmaceuticals (ARDS), Navidea Biopharmaceuticals (NAVB), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Genocea Biosciences (GNCAQ), and Genocea Biosciences (GNCA). These companies are all part of the "pharmaceutical products" industry. Vaxxinity vs. Its Competitors Syros Pharmaceuticals NexImmune Virpax Pharmaceuticals Scopus BioPharma Aridis Pharmaceuticals Navidea Biopharmaceuticals Evelo Biosciences Comera Life Sciences Genocea Biosciences Genocea Biosciences Vaxxinity (NASDAQ:VAXX) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation. Does the media prefer VAXX or SYRS? In the previous week, Vaxxinity's average media sentiment score of 0.00 equaled Syros Pharmaceuticals'average media sentiment score. Company Overall Sentiment Vaxxinity Neutral Syros Pharmaceuticals Neutral Is VAXX or SYRS more profitable? Vaxxinity's return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets VaxxinityN/A N/A N/A Syros Pharmaceuticals N/A -3,369.56%-97.04% Do analysts recommend VAXX or SYRS? Syros Pharmaceuticals has a consensus price target of $1.00, suggesting a potential upside of 999,900.00%. Given Syros Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Syros Pharmaceuticals is more favorable than Vaxxinity.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaxxinity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Syros Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do insiders & institutionals believe in VAXX or SYRS? 82.9% of Vaxxinity shares are held by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are held by institutional investors. 64.1% of Vaxxinity shares are held by insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more volatility & risk, VAXX or SYRS? Vaxxinity has a beta of 20.34, suggesting that its share price is 1,934% more volatile than the S&P 500. Comparatively, Syros Pharmaceuticals has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500. Which has better earnings & valuation, VAXX or SYRS? Vaxxinity has higher earnings, but lower revenue than Syros Pharmaceuticals. Vaxxinity is trading at a lower price-to-earnings ratio than Syros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVaxxinityN/AN/A-$56.93M-$0.45-0.04Syros Pharmaceuticals$386K0.01-$164.57M-$3.030.00 SummaryVaxxinity beats Syros Pharmaceuticals on 6 of the 11 factors compared between the two stocks. Get Vaxxinity News Delivered to You Automatically Sign up to receive the latest news and ratings for VAXX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VAXX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VAXX vs. The Competition Export to ExcelMetricVaxxinityPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.54M$876.00M$5.74B$10.43BDividend YieldN/A4.84%5.61%4.58%P/E Ratio-0.041.2176.4926.64Price / SalesN/A25.74551.27126.90Price / CashN/A17.6525.8131.15Price / Book0.186.4513.626.47Net Income-$56.93M-$5.56M$3.29B$271.57M7 Day PerformanceN/A-0.67%1.67%2.86%1 Month PerformanceN/A5.55%4.03%7.26%1 Year PerformanceN/A22.41%80.59%26.02% Vaxxinity Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VAXXVaxxinityN/A$0.02+19,900.0%N/A-99.8%$2.54MN/A-0.0490SYRSSyros Pharmaceuticals3.9474 of 5 stars$0.00flat$1.00+166,566.7%-99.7%$16K$386K0.00120Positive NewsGap DownNEXINexImmuneN/A$0.01flatN/A-96.0%$14KN/A0.0070Gap UpVRPXVirpax Pharmaceuticals0.1787 of 5 stars$0.01+9.9%N/A-99.9%$14KN/A0.007SCPSScopus BioPharmaN/A$0.00flatN/AN/A$13KN/A0.009ARDSAridis PharmaceuticalsN/A$0.00-84.6%N/AN/A$11KN/A0.0030Gap DownNAVBNavidea BiopharmaceuticalsN/A$0.00-80.0%N/A-90.0%$10K$8.13K0.0010High Trading VolumeEVLOEvelo BiosciencesN/A$0.00flatN/AN/A$9KN/A0.00120CMRAComera Life SciencesN/A$0.00flatN/AN/A$6K$1.00M0.002GNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6K$1.91M0.0070 Related Companies and Tools Related Companies Syros Pharmaceuticals Competitors NexImmune Competitors Virpax Pharmaceuticals Competitors Scopus BioPharma Competitors Aridis Pharmaceuticals Competitors Navidea Biopharmaceuticals Competitors Evelo Biosciences Competitors Comera Life Sciences Competitors Genocea Biosciences Competitors Genocea Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VAXX) was last updated on 9/23/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredRefund From 1933: Trump’s Reset May Create Instant WealthTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxxinity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxxinity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VAXX Stock Alerts